Physics Nobel Prize for contributions to Attosecond Physics 

The Nobel Prize in Physics 2023 has been awarded to Pierre Agostini, Ferenc Krausz and Anne L’Huillier “for experimental methods that generate attosecond pulses of light for the study of electron dynamics in matter”.  

An attosecond is one quintillionth of a second (equal to 1×10−18 second). It is so short that there are as many in one second as there have been seconds since the birth of the universe

In the world of electrons, changes occur in a few tenths of an attosecond. The special technology creates extremely short pulses of light that can be used to measure the rapid processes in which electrons move or change energy inside atoms and molecules. 

The laureates’ contributions have made “attosecond physics” a reality which has potential applications in many areas such as study of behaviour of electrons in a material, electronics and medical diagnostics.  

*** 

Sources:  

  1. Nobelprize.org. The Nobel Prize in Physics 2023. Available at https://www.nobelprize.org/prizes/physics/2023/summary/ 
  1. Nobelprize.org . Press release – The Nobel Prize in Physics 2023. Posted on 3 October 2023. Available at https://www.nobelprize.org/prizes/physics/2023/press-release/  

***

Latest

Brain-Computer Interfaces (BCI): Towards Humans’ Merger with AI 

The ongoing clinical trials of Brain-Computer Interfaces (BCIs) such...

Tumour Treating Fields (TTFields) approved for Pancreatic cancer

Cancer cells have electrically charged parts hence are influenced...

Scientific European invites Co-founder

Scientific European (SCIEU) invites you to join as a Co-Founder and investor, with both...

Future Circular Collider (FCC): CERN Council reviews Feasibility Study

The quest for the answers to the open questions (such as, which...

Chernobyl Fungi as Shield Against Cosmic Rays for Deep-Space Missions 

In 1986, the 4th unit of Chernobyl Nuclear Power Plant in Ukraine...

Myopia Control in Children: Essilor Stellest Eyeglass Lenses Authorised  

Myopia (or near-sightedness) in children is a highly prevalent...

Newsletter

Don't miss

CD24: an Anti-Inflammatory Agent for Treatment of COVID-19 Patients

The researchers at the Tel-Aviv Sourasky Medical Center have successfully completely Phase...

A Way Forward in Developing Medicines with Fewer Unwanted Side Effects

A breakthrough study has shown a way forward to...

Irish Research Council Takes Several Initiatives to Support Research

Irish government announces €5 million in funding to support...

Generative Artificial Intelligence (AI): WHO issues new Guidance on governance of LMMs

WHO has issued new guidance on the ethics and...

UK’s First Birth Following Living-donor Uterine Transplantation

The woman who had undergone the first living-donor uterus...

Would Synthetic Embryos Usher in the Era of Artificial Organs?   

Scientists have replicated the natural process of mammalian embryonic...
SCIEU Team
SCIEU Teamhttps://www.scientificeuropean.co.uk
Scientific European® | SCIEU.com | Significant advances in science. Impact on humankind. Inspiring minds.

Brain-Computer Interfaces (BCI): Towards Humans’ Merger with AI 

The ongoing clinical trials of Brain-Computer Interfaces (BCIs) such as Neuralink’s “Telepathy” implant involve establishing communication links between the brains of participants who have unmet medical needs due...

Tumour Treating Fields (TTFields) approved for Pancreatic cancer

Cancer cells have electrically charged parts hence are influenced by electric fields. Application of alternating electric fields (TTFields) to solid tumours selectively target and...

Scientific European invites Co-founder

Scientific European (SCIEU) invites you to join as a Co-Founder and investor, with both strategic investment and active contribution in shaping its future direction.  Scientific European is an England-based media outlet providing multilingual...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

For security, use of Google's reCAPTCHA service is required which is subject to the Google Privacy Policy and Terms of Use.

I agree to these terms.